GlassScriptPhysician profile
Barbara L Hoffman
NPI 1043656721
$2,861.07
in general payments reported to CMS, 2019-2025
17 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $135 · 2022: $745 · 2023: $1,218 · 2024: $647 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,980.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $593.86 | 2021-2024 | Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $583.12 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $469.57 | 2023-2024 | Uzedy, Austedo Xr, Austedo |
| Vanda Pharmaceuticals INC. | $327.91 | 2022-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $270.31 | 2021-2024 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $146.37 | 2021-2024 | Ingrezza |
| Lundbeck LLC | $80.37 | 2023 | Rexulti |
| Ferring Pharmaceuticals INC. | $68.61 | 2023-2025 | Euflexxa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.01 | 2022-2023 | |
| Indivior INC. | $62.33 | 2022-2024 | Perseris |
| Novo Nordisk INC | $43.04 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $33.07 | 2021-2023 | Trintellix |
| Sunovion Pharmaceuticals INC. | $32.79 | 2021-2022 | |
| Axsome Therapeutics, INC. | $30.37 | 2023-2025 | Auvelity |
| Pfizer INC. | $20.80 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $20.02 | 2023 | Loreev Xr |
| Janssen Pharmaceuticals, INC | $12.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.